The estimated Net Worth of Alan F Schatzberg is at least $86.8 Milhão dollars as of 30 March 2007. Alan Schatzberg owns over 50,000 units of Corcept Therapeutics Inc stock worth over $86,697,527 and over the last 19 years Alan sold CORT stock worth over $109,179.
Alan has made over 2 trades of the Corcept Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Alan bought 50,000 units of CORT stock worth $50,000 on 30 March 2007.
The largest trade Alan's ever made was buying 50,000 units of Corcept Therapeutics Inc stock on 30 March 2007 worth over $50,000. On average, Alan trades about 32,799 units every 296 days since 2005. As of 30 March 2007 Alan still owns at least 2,438,749 units of Corcept Therapeutics Inc stock.
You can see the complete history of Alan Schatzberg stock trades at the bottom of the page.
Alan's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson, eVentures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: